The Independent Beauty Association aims to be more proactive in its US legislative advocacy work under Don Frey, appointed president and CEO of the trade group in July.
IBA President Don Frey On 'Inside The Box' Innovation And Sensible Cosmetics Legislation
The Honest Company alum brings to the Independent Beauty Association an extensive R&D background and the conviction that constraints on businesses today can and should foster innovation. That said, unduly burdensome legislation threatens to have a stifling effect on cosmetics innovation, the group’s new president and CEO tells HBW Insight in Part 2 of this interview.
More from Leadership
• By
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
More from HBW Insight
• By
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.